Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 4721

Drug Profile

AZD 4721

Alternative Names: AZD4721; RIST4721

Latest Information Update: 01 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Aristea Therapeutics; AstraZeneca
  • Class Antibronchitics; Skin disorder therapies
  • Mechanism of Action Interleukin 8B receptor antagonists; Interleukin-8B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Palmoplantar pustulosis
  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 19 Nov 2019 Aristea Therapeutics completes a phase IIa trial for Palmoplantar pustulosis in Germany and Canada (NCT03988335)
  • 17 Oct 2019 Aristea Therapeutics completes enrolment in a phase IIa trial for Palmoplantar pustulosis in Germany and Canada (NCT03988335)
  • 13 Feb 2019 Phase-II clinical trials in Palmoplantar pustulosis in Germany (PO) (NCT03988335)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top